Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379562 | 0.74 | KDM4E (0.32) | ALDH1A1 | |
| SCHEMBL14250711 | 0.72 | F2 (0.33) | CTSD | |
| SCHEMBL31267954 | 0.72 | F2 (0.33) | CTSD | |
| SCHEMBL14250714 | 0.72 | F2 (0.33) | CTSD | |
| SCHEMBL18708199 | 0.69 | F2 (0.34) | — | |
| SCHEMBL20758414 | 0.69 | L3MBTL1 (0.34) | ALDH1A1 | |
| SCHEMBL20758335 | 0.68 | — | — | |
| SCHEMBL15543154 | 0.68 | F2 (0.41) | CTSD | |
| SCHEMBL3059572 | 0.67 | OR51E2 (0.46) | CRBNALDH1A1 | |
| SCHEMBL6217007 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432278-B2 | Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-10-07 | — | — | US | claimed |
| EP-1745045-A2 | NOVEL DICATIONIC IMIDAZO 1,2-a PYRIDINES AND 5,6,7,8-TE TRAHYDRO-IMIDAZO 1,2a PYRIDINES AS ANTIPROTOZOAL AGENTS | The University of North Carolina at Chapel Hill (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050282853-A1 | Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents | BOYKIN DAVID W | 2005-12-22 | — | — | US | claimed |
| WO-2005086808-A2 | NOVEL DICATIONIC IMIDAZO[1,2-a]PYRIDINES AND 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2a]PYRIDINES AS ANTIPROTOZOAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-22 | — | — | WO | claimed |
| EP-3947366-B1 | HPK1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4149937-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220177458-A1 | HPK1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | disclosed |
| WO-2021231571-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004005293-A2 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CTSD 3687/4885CRBN 1325/4885ALDH1A1 1936/4885 |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CTSD 2067/4885CRBN 1637/4885ALDH1A1 4119/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CTSD 4230/4885CRBN 1038/4885ALDH1A1 1292/4885 |
| US-20050282853-A1 | Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents | PBRM1, QDPR, DHPS | CTSD 3966/4885CRBN 2944/4885ALDH1A1 1820/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CTSD 2602/4885CRBN 2186/4885ALDH1A1 1429/4885 |
| US-20220177458-A1 | HPK1 INHIBITORS | PGK1, PCK1, PDXK | CTSD 2777/4885CRBN 4108/4885ALDH1A1 3839/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CTSD 4262/4885CRBN 1312/4885ALDH1A1 907/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | CTSD 2067/4885CRBN 1637/4885ALDH1A1 4119/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | CTSD 1936/4885CRBN 1815/4885ALDH1A1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.